Edgewise Therapeutics, Inc.
EWTX
Pozycja w akcjach
#3882
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Cena akcji
$39.70
Kapitalizacja rynkowa
$4.27B
Zmiana (1 dzień)
-0.12%
Zmiana (1 rok)
155.98%
Kraj
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategoria
Healthcare
Historia ceny akcji dla Edgewise Therapeutics, Inc. (EWTX)
Najwyższa cena zamknięcia: $38.97 dnia 2026-10-01
Najniższa cena zamknięcia: $32.43 dnia 2021-03-01
Najniższa cena zamknięcia: $32.43 dnia 2021-03-01
Historia cen akcji firmy Edgewise Therapeutics, Inc. od 2021 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 37.71% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
